Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2021, with a specific reporting date of January 26, 2021. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADSs) |
| Transaction Date | January 22, 2021 |
| Transaction Price | $38.36 per ADS |
| Total Volume | 1,294.246 ADSs (1,098.246 via Supplemental Savings Plan; 196 via 401(k) Plan) |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely documents the acquisition of shares by an executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a routine disclosure of an executive's participation in company savings plans.
Key Facts for Investor Verification
- Executive Identity: The transaction involves Dr. H. Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: The shares were acquired through automatic payroll deductions into the GSK Executive Supplemental Savings Plan and the GSK 401(k) Plan, not via open market purchases.
- Valuation: The transaction occurred at a price of $38.36 per ADS on January 22, 2021.
- Scope: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.